Study of improvement effect by switching to duraglutide or addition of empagliflozin to patients mith poor blood glucose control under multidrug combination including dipeptidyl peptidase-4inhibitor(Randomized openlabel comparative clinical study)

Study of improvement effect by switching to duraglutide or addition of empagliflozin to patients mith poor blood glucose control under multidrug combination including dipeptidyl peptidase-4inhibitor(Randomized openlabel comparative clinical study) - Study of improvement effect by switching to duraglutide or addition of empagliflozin to patients mith poor blood glucose control under multidrug combination including dipeptidyl peptidase-4inhibitor(Randomized openlabel comparative clinical study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027913

Enrollment

Registered

2017-06-25

Start date

2017-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes

Interventions

change to GLP1receptor agonist (dulaglutide 0.75mg s.c.) add on SGLT2inhibitor (empagliflozin 10mg p.o.)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetes treat with dpp4inhibitor

Exclusion criteria

Exclusion criteria: over 65 age insulin user

Design outcomes

Primary

Measure	Time frame
HbA1c(16 weeks later)	—

Secondary

Measure	Time frame
glucose,hypoglycemia frequency,LDL-cholesterol,triglyceride,AST,ALT,BUN,creatinine,hyper tension	—

Countries

Japan

Contacts

Public ContactIwashita Ayako

Juntendo university hospital diabetes

kawasumi@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026